BILL ANALYSIS

HR1990

BULLISH

American Innovation and R&D Competitiveness Act of 2025

HR1990 (American Innovation and R&D Competitiveness Act of 2025) has been assessed with a bullish outlook for investors. The primary sectors impacted are Technology, Healthcare and Manufacturing. View the full bill text on Congress.gov.

bullish

Market Sentiment

6/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

HR1990 would restore immediate R&D expensing, directly increasing after-tax cash flow for every R&D-intensive US company by 21% of their R&D spend annually

Largest absolute beneficiaries are mega-cap tech and pharma with $10B+ R&D budgets: $AMZN, $GOOGL, $MSFT, $AAPL, $NVDA, $MRK, $LLY, $PFE

Bill is early stage (referred to Ways and Means), has 81 Republican cosponsors, no Senate companion — passage is not imminent and requires significant legislative momentum

How HR1990 Affects the Market

A bill restoring immediate R&D expensing is structurally bullish for US R&D-intensive companies. The tax mechanism directly improves free cash flow by allowing companies to deduct R&D costs in Year 1 rather than spreading over 5 years. For $MSFT, $AAPL, and $NVDA — each with $10B-$30B in annual R&D — the cash flow benefit is $2-6B per year. For $AMZN, at $60B R&D, the annual benefit exceeds $12B. The bill is not priced into current valuations because of its early stage; passage would represent a meaningful tax cut for the growth sectors of the US economy. Failure to pass (or prolonged delay) maintains the current amortization regime, which is a headwind for high-R&D companies relative to the pre-2022 tax treatment.

Bill Details

Metric	Value
Bill Number	HR1990
Market Sentiment	bullish
Event Date	March 10, 2025
Affected Sectors	Technology, Healthcare, Manufacturing
Source	View on Congress.gov →

Summary

HR1990, the American Innovation and R&D Competitiveness Act, would restore immediate expensing for R&D costs, reversing the 2022 tax code change that required 5/15-year amortization. This is an early-stage bill referred to Ways and Means with 81 cosponsors, but if enacted, it would provide a direct 21% tax-rate cash flow benefit annually to every R&D-intensive US company. The largest absolute beneficiaries are mega-cap tech and pharma firms with $10B+ annual R&D budgets.

Full AI Market Analysis

1) What happened: On March 10, 2025, Rep. Estes (R-KS) introduced HR1990 to restore immediate expensing for qualified R&D costs under IRC §174. The Tax Cuts and Jobs Act of 2017 required R&D costs to be amortized over 5 years (US) or 15 years (foreign) starting in 2022 — this bill would repeal that provision. The bill has 81 cosponsors (all Republicans), was referred to Ways and Means, and has no further action after introduction. It is classified as an early-stage bill with 3 total actions, all on the same day. 2) The money trail: This is a tax expenditure — it reduces federal revenue by the amount of R&D spending companies immediately deduct vs. amortizing over 5 years. HR1990 does not authorize or appropriate any spending; it changes tax treatment. The estimated revenue impact is a reduction in corporate tax receipts equal to 21% of total US business R&D annually (approximately $60-80B/year based on aggregate US R&D spend of $300-400B). This is a DIRECT cash flow benefit to R&D-intensive companies with no procurement or contract mechanism — companies simply pay less tax. 3) Structural winners: The largest US R&D spenders are the direct beneficiaries. By absolute dollar, the winners are: $AMZN (~$60B R&D), $GOOGL (~$45B), $MSFT (~$30B), $AAPL (~$30B), $NVDA (~$12B), $MRK (~$14B), $PFE (~$12B), $LLY (~$11B). By sector, semiconductors, cloud software, biotech/pharma, and industrial innovators ($CAT, $DE, $GE) benefit most. Smaller-cap R&D-intensive companies benefit proportionally more relative to market cap but in smaller absolute dollars. 4) Competitive landscape: HR1990 does not pick winners by sector — it benefits any US corporation with R&D expenses. However, the structural impact favors companies with high R&D-to-revenue ratios (tech, pharma) over asset-heavy, low-R&D sectors (utilities, real estate, consumer staples). For $AMZN and $GOOGL with massive cloud R&D, the bill directly supports margin expansion without requiring top-line growth. For $UNH, the Optum health-tech R&D spend qualifies — a secondary beneficiary. 5) Timeline: HR1990 is at the earliest legislative stage (referred to committee, no hearings yet). Passage probability is low-to-moderate in the 119th Congress given the partisan nature of tax bills and limited cosponsorship (81 total, all Republican). The earliest action would be a Ways and Means markup, then House floor vote, then Senate Finance Committee consideration. Given no companion Senate bill with matching text, the legislative path is long — likely 12-18 months minimum if it gains momentum. Related bills (HR3967, S1639, S2056) show bipartisan interest in R&D expensing but no unified vehicle.